- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
21 result(s) found for: Capox.
Displaying page 1 of 2.
EudraCT Number: 2018-000519-26 | Sponsor Protocol Number: 8951-CL-0302 | Start Date*: 2019-02-13 | |||||||||||
Sponsor Name:Astellas Pharma Global Development, Inc. (APGD) | |||||||||||||
Full Title: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin (CLD... | |||||||||||||
Medical condition: Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) NL (Completed) ES (Restarted) AT (Prematurely Ended) PT (Trial now transitioned) GR (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) HR (Completed) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000507-20 | Sponsor Protocol Number: CIRCULATE-SPAIN-01 | Start Date*: 2022-01-12 | ||||||||||||||||
Sponsor Name:Instituto de Investigación Sanitaria INCLIVA | ||||||||||||||||||
Full Title: Phase II randomized trial to assess the effect of intensive vs standard adjuvant chemotherapy in localised colon cancer with circulating tumor DNA | ||||||||||||||||||
Medical condition: Localised Colon Cancer (stage II-III) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002214-17 | Sponsor Protocol Number: NL78220.029.21 | Start Date*: 2023-04-24 | ||||||||||||||||
Sponsor Name:Amsterdam University Medical Centers | ||||||||||||||||||
Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial | ||||||||||||||||||
Medical condition: Recurrent colorectal liver metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003477-61 | Sponsor Protocol Number: 20210098 | Start Date*: 2022-07-13 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Canc... | ||||||||||||||||||
Medical condition: Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b Overexpression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) PL (Trial now transitioned) BE (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) CZ (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) RO (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002074-32 | Sponsor Protocol Number: IFOM-CPT005/2019/PO004 | Start Date*: 2020-02-11 | |||||||||||
Sponsor Name:IFOM - Istituto FIRC di Oncologia Molecolare | |||||||||||||
Full Title: POST-SURGICAL LIQUID BIOPSY-GUIDED TREATMENT OF STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS | |||||||||||||
Medical condition: Stage III and high-risk stage II colon cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001989-36 | Sponsor Protocol Number: SIGN | Start Date*: 2022-09-07 |
Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie | ||
Full Title: Selective serotonin reuptake inhibition in patients with advanced gastroesophageal cancer receiving immunochemotherapy: a prospective phase II trial | ||
Medical condition: gastroesophageal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002767-26 | Sponsor Protocol Number: LyRICX | Start Date*: 2019-06-25 |
Sponsor Name:Academic Medical Center | ||
Full Title: Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) | ||
Medical condition: gastroesophageal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-002588-23 | Sponsor Protocol Number: 2019/0407/HP | Start Date*: 2023-03-13 | ||||||||||||||||
Sponsor Name:CHU de Rouen | ||||||||||||||||||
Full Title: Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy: A randomized phase III trial - COnCERTO (French 01-18) | ||||||||||||||||||
Medical condition: Patients first treated by stoma and requiring chemotherapy for obstructive colon cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020787-37 | Sponsor Protocol Number: 8159 | Start Date*: 2013-01-28 |
Sponsor Name:Universitair Medisch Centrum Groningen | ||
Full Title: Neo-adjuvant chemotherapy, cytoreductive surgery with hyperthermic intra-peritoneal chemotherapy for peritoneal carcinomatosis of colorectal origin (NACHO-trial) | ||
Medical condition: peritoneal carcinomatosis of colorectal origin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000267-29 | Sponsor Protocol Number: 0059718/05GENII6A | Start Date*: 2006-01-01 | |||||||||||
Sponsor Name:Centro sociale oncologico | |||||||||||||
Full Title: Adjuvant chemotherapy in stage III colon carcinoma in patients age or 70 years. Feasibility of CAPOX scheme oxaliplatin 70 mg/mq days 1-8 and capecitabine 1000 mg/mq X 2 die days 1-14 every 21 da... | |||||||||||||
Medical condition: Colon carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005326-23 | Sponsor Protocol Number: PHRC-K2020PEZET | Start Date*: 2022-01-24 |
Sponsor Name:CHU de Clermont-Ferrand | ||
Full Title: Evaluation of the efficacy of donepezil in the treatment of oxaliplatin-induced peripheral neuropathy: proof of concept study | ||
Medical condition: Oxaliplatine-induced peripheral neuropathy | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-003697-52 | Sponsor Protocol Number: SYNCOPE-2021-V1 | Start Date*: 2020-09-16 | |||||||||||
Sponsor Name:Helsinki University Hospital | |||||||||||||
Full Title: Systemic Neoadjuvant and adjuvant Control by Precision medicine in rectal cancer (SYNCOPE) – approach on high-risk group to reduce metastases | |||||||||||||
Medical condition: Rectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001067-79 | Sponsor Protocol Number: ColoAd1-1001 | Start Date*: 2012-08-21 | |||||||||||
Sponsor Name:Psioxus Therapeutics Ltd. | |||||||||||||
Full Title: A Phase I / II Dose Escalation and Randomised Controlled Trial of ColoAd1 Administered by Sub-acute Fractionated Intravenous Injection to Patients with Metastatic Colorectal Cancer | |||||||||||||
Medical condition: metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000698-22 | Sponsor Protocol Number: MK-7339-003 | Start Date*: 2020-02-26 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with a Fluoropyrimidine in Participants with ... | |||||||||||||
Medical condition: The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) FR (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003009-40 | Sponsor Protocol Number: CCR4326 | Start Date*: 2015-12-18 | |||||||||||||||||||||
Sponsor Name:Royal Marsden NHS Foundation Trust | |||||||||||||||||||||||
Full Title: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good And Poor Responders To Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial | |||||||||||||||||||||||
Medical condition: Rectal cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005329-56 | Sponsor Protocol Number: ma1229 | Start Date*: 2013-06-06 | |||||||||||
Sponsor Name:Dept of oncology | |||||||||||||
Full Title: A phase ll trial of combination chemotherapy with intravenous oxaliplatin combined with tablet capecitabin in patients with recidivant breastcancer | |||||||||||||
Medical condition: breastcancer with metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014407-31 | Sponsor Protocol Number: 09.07 | Start Date*: 2009-10-06 | |||||||||||
Sponsor Name:Odense Universitetshospital | |||||||||||||
Full Title: Randomiseret fase II forsøg med irinotecan, cetuximab og everolimus (ICE) sammenlignet med capecitabin og oxaliplatin (CapOx) til patienter med gemcitabin resistent pancreascancer. | |||||||||||||
Medical condition: Patienter med gemcitabin resistent pancreascancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002141-42 | Sponsor Protocol Number: NL73593 | Start Date*: 2020-07-03 |
Sponsor Name:Catharina Hospital | ||
Full Title: Multicentre, open-label, randomised, controlled, parallel arms clinical trial of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for loc... | ||
Medical condition: Locally recurrent rectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) PT (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005437-32 | Sponsor Protocol Number: ERASE-TMZ | Start Date*: 2021-03-10 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | ||||||||||||||||||
Full Title: Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuva... | ||||||||||||||||||
Medical condition: Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000767-17 | Sponsor Protocol Number: IRST100.22 | Start Date*: 2017-01-18 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: A randomized phase II trial of captem or folfiri as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study) | |||||||||||||
Medical condition: Neuroendocrine Carcinomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
